It’s no secret that #WeLoveWhatWeDo at Apellis. We are passionate about our work, our purpose, and the positive impact we can make. Learn more about our culture: https://lnkd.in/ezckD-Ns #WeAreApellis
Apellis Pharmaceuticals
Biotechnology Research
Waltham, MA 70,770 followers
Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies.
Über uns
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
- Website
-
https://apellis.com/
External link for Apellis Pharmaceuticals
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- Waltham, MA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2008
- Spezialitäten
- Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
Standorte
-
Primäre
Wegbeschreibung erhalten
100 Fifth Ave
3rd Floor
Waltham, MA 02451, US
-
Wegbeschreibung erhalten
720 Market Street
5. Stockwerk
San Francisco, California 94102, US
-
Wegbeschreibung erhalten
Zählerweg 10
Zug, 6300, CH
Employees at Apellis Pharmaceuticals
-
Beth Marsh
Commercial Strategy and Launch | Sales Management | Business Development | Training & Development
-
Alexandre de Jesus
Associate Director @ Apellis Pharmaceuticals | Commercial Operations Excellence
-
Renaud Desgraz, PhD
-
Lisa Paul-Stark
Patient focused rare disease medical sales professional with over 20 years of success, including more than 18 years in rare/Orphan disease, focusing…
Aktualisierungen
-
We're inspired every day by the rare disease community. Hear from Ashley about how living with a rare disease like #PNH has changed her outlook on life. #WeAreApellis
-
Are you up for the challenge? Test your #GeographicAtrophy (GA) knowledge with #ApellisEyeQ! *Geographic Atrophy Insights Survey (GAINS) (N=203) was conducted by The Harris Poll and sponsored by Apellis Pharmaceuticals*
This content isn’t available here
Access this content and more in the LinkedIn app
-
There are currently no approved treatment options for C3G or IC-MPGN – rare kidney diseases which can lead to kidney failure within five to 10 years of diagnosis. We strive to understand the unique challenges people with rare diseases face and are committed to always putting patients first. Learn more about our latest news in C3G and IC-MPGN: https://bit.ly/3yjqUxe
-
Exciting news! 🎉 We’re thrilled to share positive topline results from our Phase 3 VALIANT study in C3G and IC-MPGN, which are rare kidney diseases with no approved treatment: https://bit.ly/3yjqUxe
-
-
When the complement cascade is overactivated, it can lead to serious diseases. Learn more about how our world-class researchers at #Apellis are focused on finding targeted C3 therapies to address diseases with high unmet need: https://bit.ly/45NXkLy #WeAreApellis
-
-
Today, we are proud to share our Q2 2024 financial results and highlights. $APLS https://bit.ly/4dn3fus
-
-
To be an Apellucian is to be part of a community dedicated to life-changing work. Our value of #WeAreFearless means we embrace risks to stretch and achieve extraordinary results - while having fun along the way! Learn more about our values and culture: https://lnkd.in/ezckD-Ns #WeAreApellis
-
We’re fearless in the fight against vision loss on behalf of the more than 5 million people globally who live with #GeographicAtrophy (GA), which leads to progressive and irreversible vision loss. Attending #ASRS2024? Learn more about how to support your patients living with GA at booth 411. #WeAreApellis
-
-
Hello from Sweden! 👋 Attending #ASRS2024? Come meet the team and learn more about our work in #GeographicAtrophy (GA) at booth #411. #WeAreApellis
-